藥石科技(300725.SZ)上半年營收增37.8%至2.9億元
格隆匯8月22日丨藥石科技(300725.SZ)公佈2019上半年業績,公司實現營業收入2.9億元,較上年同期增加37.8%;實現營業利潤7625.81萬元,較上年同期增加30.88%;實現利潤總額7924.8萬元,較上年同期增加30.07%;2019年半年度實現歸屬於上市公司股東的淨利潤6926.79萬元, 較上年同期增加30.31%;扣除非經常性損益的淨利潤6531.68萬元,較上年同期增加35.28%。
公司商務團隊在過去半年中拜訪了位於亞洲、歐洲和北美等地區數十家重點客户及新客户,持續關注他們的研發管線進展和產品服務需求,努力建立長期、多項目以及覆蓋新藥研發早期、臨牀前開發期、臨牀試驗階段和商業化階段的全面廣泛合作。2019年上半年,公司接待了數十多家國內外領先醫藥研發公司的審計和參觀,並獲得客户對公司技術實力、質量控制及安全環保管理的高度認可。
藉助公司不斷壯大的計算化學和藥物化學能力,分子設計團隊在2019年上半年強化新穎獨特分子砌塊的設計以及新合成方法的開拓,共設計4000餘個分子砌塊,開發合成了1000多個有特色的分子砌塊;2019年上半年提交了8個CN專利申請和1個PCT專利申請。
公司基於在分子砌塊設計、合成中積累的經驗和優勢,順應客户項目進入臨牀前、臨牀開發階段對分子砌塊及高級中間體需求的提升,公司不斷加強工藝開發和放大生產能力,並建立了連續流化學、微反應、酶催化、氟化學等先進的技術平台,以促進更加高效、綠色的化學生產。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.